iBio will be long term winner
iBio (IBIO) currently trades at $0.98 and has fallen by 3.42% today. Founded in 2008, iBio is a plant-based expression biologics contract development and manufacturing organization (CDMO). Essentially, it helps with the clinical development of treatments. It was in early February that IBIO stock started its surge. The company announced a collaboration with Beijing CC-Pharming to develop and test a coronavirus vaccine.
Based on this information, investorsQ rates this stock 6 out of 10. We give it this rating based on current information. If this effort proves successful, the treatment will be manufactured at scale with iBio’s FastPharming system. The high forecast for iBio is $30.00 and the low is $10.00. Notably, the company’s market cap is $98.40 million with a 52 week high of $3.40 and a 52 week low of $0.05.